Cost-effectiveness of TNF inhibitors vs synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a Markov model study based on two longitudinal observational studies (vol 54, pg 1226, 2015)

被引：1
|
作者：
Kvamme, Maria K. [1 ,2 ,3 ]
Lie, Elisabeth [1 ]
Uhlig, Till [1 ]
Moger, Tron A. [2 ]
Kvien, Tore K. [1 ]
Kristiansen, Ivar S. [2 ]
机构：
[1] Univ Oslo, Diakonhjemmet Hosp, Dept Rheumatol, Oslo, Norway
[2] Univ Oslo, Dept Hlth Management & Hlth Econ, Oslo, Norway
[3] Norwegian Knowledge Ctr Hlth Serv, POB 7004 St Olavs Plass, N-0130 Oslo, Norway
来源：
RHEUMATOLOGY | 2020年 / 59卷 / 04期
关键词：
D O I：
10.1093/rheumatology/kez609
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：917 / 917
页数：1
相关论文
共 29 条
  • [1] Cost-effectiveness of TNF inhibitors vs synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a Markov model study based on two longitudinal observational studies
    Kvamme, Maria K.
    Lie, Elisabeth
    Uhlig, Till
    Moger, Tron A.
    Kvien, Tore K.
    Kristiansen, Ivar S.
    RHEUMATOLOGY, 2015, 54 (07) : 1226 - 1235
  • [2] Cost-effectiveness of Anbainuo plus methotrexate compared to conventional disease-modifying antirheumatic drugs for rheumatoid arthritis patients in China
    Tian, Feng
    Wen, Zhenhua
    Li, Jingyang
    Luo, Xiaowen
    Deng, Li
    Zhang, Liang
    He, Jingyun
    Yao, Fangling
    Liao, Zheng
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (14)
  • [3] Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naive patients with rheumatoid arthritis
    Lauper, Kim
    Mongin, Denis
    Iannone, Florenzo
    Kristianslund, Eirik K.
    Kvien, Tore K.
    Nordstrom, Dan C.
    Pavelka, Karel
    Pombo-Suarez, Manuel
    Rotar, Ziga
    Santos, Maria J.
    Codreanu, Catalin
    Lukina, Galina
    Gale, Sara L.
    John, Markus
    Luder, Yves
    Courvoisier, Delphine S.
    Gabay, Cem
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2020, 50 (01) : 17 - 24
  • [4] Comparative effectiveness of treatment with the first TNF antagonist in monotherapy, the first TNF antagonist plus one conventional synthetic disease-modifying antirheumatic drug, and the first TNF antagonist plus two or more conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
    Hernandez-Cruz, Blanca
    Marquez-Saavedra, Esther
    Caliz-Caliz, Rafael
    Navarro-Sarabia, Federico
    ARTHRITIS RESEARCH & THERAPY, 2016, 18
  • [5] Comparative effectiveness of treatment with the first TNF antagonist in monotherapy, the first TNF antagonist plus one conventional synthetic disease-modifying antirheumatic drug, and the first TNF antagonist plus two or more conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
    Blanca Hernández-Cruz
    Esther Márquez-Saavedra
    Rafael Caliz-Caliz
    Federico Navarro-Sarabia
    Arthritis Research & Therapy, 18
  • [6] Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a Register study
    Joensuu, Jaana T.
    Aaltonen, Kalle J.
    Aronen, Pasi
    Sokka, Tuulikki
    Puolakka, Kari
    Tuompo, Riitta
    Korpela, Markku
    Vasala, Mikko
    Ilva, Kirsti
    Nordstrom, Dan
    Blom, Marja
    RHEUMATOLOGY, 2016, 55 (10) : 1803 - 1811
  • [7] COST-EFFECTIVENESS ANALYSIS OF BIOLOGICAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN THE TREATMENT OF RUSSIAN PATIENTS WITH RHEUMATOID ARTHRITIS WHO FAILED PREVIOUS ANTI-TNF-ALFA THERAPY
    Ryazhenov, V. V.
    Emchenko, I., V
    VALUE IN HEALTH, 2013, 16 (07) : A562 - A563
  • [8] COMPARATIVE EFFECTIVENESS OF TOCILIZUMAB AS MONOTHERAPY VERSUS TNF INHIBITORS IN COMBINATION WITH CONVENTIONAL SYNTHETIC DISEASE MODIFYING ANTIRHEUMATIC DRUGS IN BIONAIVE PATIENTS WITH RHEUMATOID ARTHRITIS
    Lauper, K.
    Kvien, T. K.
    Codreanu, C.
    Hernandez, M. V.
    Ianonne, F.
    Kristianslund, E. K.
    Lukina, G.
    Nordstrom, D. C.
    Pavelka, K.
    Rotar, Z.
    Santos, M. J.
    Gale, S. L.
    John, M.
    Luder, Y.
    Courvoisier, D. S.
    Gabay, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 320 - 321
  • [9] Cost-Effectiveness of Combination Disease-Modifying Antirheumatic Drugs Versus Tumor Necrosis Factor Inhibitors in Active Rheumatoid Arthritis: A Pragmatic, Randomized, Multicenter Trial
    Patel, Anita
    Heslin, Margaret
    Scott, David L.
    Stringer, Dominic
    Birrell, Fraser
    Ibrahim, Fowzia
    ARTHRITIS CARE & RESEARCH, 2020, 72 (03) : 334 - 342
  • [10] Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study
    Gulsen Ozen
    Sofia Pedro
    Rebecca Schumacher
    Teresa A. Simon
    Kaleb Michaud
    Arthritis Research & Therapy, 21
123